Genta Incorporated (TOCBB:GETA) will release the third quarter earnings for 2009 on Monday, November 16. The company will host a conference call on at 8:00 am ET that morning to discuss the financial results. Interested parties may hear the call by dialing 877.634.8606 or 973.200.3973 for international callers. The access code for the call will be Genta Incorporated. Those unable to join may hear a replay of the call by dialing 800.642.1687, or 706.645.9291 for international callers. The conference ID number will be 37594914 and the replay will be available for thirty days after the event. A webcast of the presentation will also be available online at www.genta.com/investorrelation/events.html.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
The company will later on present at the international Molecular Targets and Cancer Therapeutics” conference in Boston, MA to discuss the results of Genta Incorporated’s Phase 3 trial in advanced melanoma, referred to as AGENDA. The presentation is scheduled for 5:00 pm that afternoon and will cover the current results and evaluation of the survival from AGENDA.
Genta Incorporated (Genta), is a biopharmaceutical company engaged in pharmaceutical (drug) research and development. The Company focuses on the identification, development and commercialization of drugs for the treatment of cancer and related diseases. Genta’s research portfolio consists of two major programs: Deoxyribonucleic Acid (DNA)/Ribonucleic Acid (RNA) Medicines and Small Molecules. The DNA/RNA Medicines program includes drugs that are based on using modifications of either DNA or RNA as drugs that can be used to treat disease. This program includes technologies, such as antisense, decoys and small interfering or micro RNAs. Genta’s drug from this program is an investigational antisense compound known as Genasense (oblimersen sodium injection). The Small Molecules program includes drugs, such as Ganite and investigational compounds tesetaxel and G4544.
Sign up for the free Best Damn Penny Socks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
